Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 22OTHER 17UNKNOWN 2NETWORK 1

Study Type

Interventional 15Observational 1

Sponsor

Conditions

Recurrent Squamous Cell Lung Carcinoma 1

Interventions

Gene Expression Profiling 74Polymerase Chain Reaction 44Microarray Analysis 40Amplified Fragment Length Polymorphism Analysis 37Immunohistochemistry 35Flow Cytometry 30Reverse Transcriptase Polymerase Chain Reaction 22DNA Methylation 16Blotting, Western 15Cytogenetic Analysis 14Base Sequence 12Psychiatric Rehabilitation 11In Situ Hybridization, Fluorescence 10Immunologic Techniques 9Enzyme-Linked Immunosorbent Assay 7Mental Status and Dementia Tests 6Comparative Genomic Hybridization 6Watchful Waiting 5Specimen Handling 5Pharmacogenomic Testing 5Mass Spectrometry 5Gene Rearrangement 5Chromosome Mapping 5Surveys and Questionnaires 4Surgical Procedures, Operative 4Rituximab 4Paclitaxel 4Interviews as Topic 4In Situ Hybridization 4Immunoenzyme Techniques 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Observational × palbociclib × Clear all
NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡